Dengue human infection models to advance dengue vaccine development

Vaccine

Volumn 33, Issue 50, 2015, Pages 7075-7082

  Larsen, Christian P ^a   Whitehead, Stephen S ^b   Durbin, Anna P ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Dengue; Dengue vaccine; Human challenge model; Human infection model

Indexed keywords

ALANINE AMINOTRANSFERASE; DENGUE VACCINE; LIVE VACCINE; PROTHROMBIN;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; DENGUE; DENGUE VIRUS 2; DENGUE VIRUS 3; DISEASE MODEL; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MALE; MYALGIA; NEUTROPENIA; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTHROMBIN TIME; RASH; SEROCONVERSION; SEROTYPE; SIDE EFFECT; THROMBOCYTOPENIA; VIREMIA; VIRUS ATTENUATION; ANIMAL; DENGUE VIRUS; DRUG DEVELOPMENT; GENETICS; HUMAN EXPERIMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES; UNITED STATES; VIROLOGY; YOUNG ADULT;

ADULT; ANIMALS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

EID: 84952639052     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.052     Document Type: Article

References (48)

1. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, April (496)(7446):504-507.
2. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998, 11(3):480-496.
3. WHO Dengue: guidelines for diagnosis, treatment, prevention, and control 2009, World Health Organization, Geneva.
4. Sabin A. Research on dengue during World War II. Am J Trop Med Hyg 1952, 1(1):30-50.
5. Innis B.L. Antibody responses to dengue virus infection. Dengue and dengue hemorrhagic fever 1997, 221-243. CAB International, Cambridge. D.J. Gubler, G. Kuno (Eds.).
6. Papaevangelou G., Halstead S.B. Infections with two dengue viruses in Greece in the 20th century. Did dengue hemorrhagic fever occur in the 1928 epidemic?. Am J Trop Med Hyg 1977, 80:46-51.
7. Burke D.S., Nisalak A., Johnson D.E., Scott R.M. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988, 38(1):172-180.
8. Kliks S.C., Nimmanitya S., Nisalak A., Burke D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988, 38(2):411-419.
9. Guzman M.G., Kouri G.P., Bravo J., Soler M., Vazquez S., Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990, 42(February (2)):179-184.
10. Halstead S.B., Chow J., Marchette N.J. Immunologic enhancement of dengue virus replication. Nat New Biol 1973, 243(122):24-26.
11. Halstead S.B., Marchette N.J., Chow J.S., Lolekha S. Dengue virus replication enhancement in peripheral blood leukocyte from immune human beings (39160). Soc Exp Biol Med 1976, 151:136-139.
12. Halstead S.B., O'Rourke E.J. Dengue viruses and mononuclear phagocytes I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977, 146(1):201-217.
13. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181(1):2-9.
14. Fox A., Le N.M., Simmons C.P., Wolbers M., Wertheim H.F., Pham T.K., et al. Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. PLoS Negl Trop Dis 2011, 5(3):e967.
15. Murgue B., Roche C., Chungue E., Deparis X. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J Med Virol 2000, 60(4):432-438.
16. Gibbons R.V., Kalanarooj S., Jarman R.G., Nisalak A., Vaughn D.W., Endy T.P., et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 2007, 77(November (5)):910-913.
17. Olkowski S., Forshey B.M., Morrison A.C., Rocha C., Vilcarromero S., Halsey E.S., et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 2013, 208(September (6)):1026-1033.
18. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380(9853):1559-1567.
19. Capeding M.R., Tran N.H., Hadinegoro S.R.S., Ismail H.I.H.J.M., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014.
20. Villar L., Dayan G.H., Arredondo-Garcia J.L., Rivera D.M., Cunha R., Deseda C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2014.
21. Graham H. Dengue: a study of its mode of propagation and pathology. Med Rec NY 1902, 61:204-207.
22. Ashburn P.M., Craig C.F. Experimental investigations regarding the etiology of dengue fever. J Infect Dis 1907, 4:440-475.
23. Cleland J.B., Bradley B., MacDonald W. Further experiments in the etiology of dengue fever. J Hyg 1919, 18(3):217-254.
24. Siler J.F., Hall M.W., Hitchens A.P. Dengue: its history, epidemilogy, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention. Philipp J Sci 1926, 29:1-304.
25. Simmons J., St John J., Reynolds F. Experimental studies of dengue. Philipp J Sci 1931, 44:1-247.
26. Sabin A.B., Schlesinger R.W. Production of immunity to dengue with virus modified by propagation in mice. Science 1945, 101:640-642.
27. Wisseman C.L., Sweet B.H., Rosenzweig E.C., Eylar O.R. Attenuated living type 1 dengue vaccines. Am J Trop Med Hyg 1963, 12:620-623.
28. Wisseman C.L. Prophylaxis of dengue, with special reference to live virus vaccine. Proc Jpn Soc Trop Med 1966, 7:51-56.
29. Sun W., Eckels K.H., Putnak J.R., Lyons A.G., Thomas S.J., Vaughn D.W., et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis 2013, 207(January (5)):700-708.
30. Mammen M.P., Lyons A., Innis B.L., Sun W., McKinney D., Chung R.C., et al. Evaluation of dengue virus strains for human challenge studies. Vaccine 2014, 32(13):1488-1494.
31. Dengue and dengue hemorrhagic fever 2014, CABI, UK. 2nd ed.
32. Dengue: guidelines for diagnosis, treatment, prevention and control: New Edition. Geneva 2009.
33. Simmons C.P., Farrar J.J., Nguyen v V., Wills B. Dengue. N Engl J Med 2012, 366(15):1423-1432.
34. Carpenter D.N., Sutton R.L. Dengue in the Isthmian Canal Zone including a report on the laboratory findings. JAMA 1905, 44:214-216.
35. Kuo C.H., Tai D.I., Chang Chien C.S., Lan C.K., Chiou S.S., Liaw Y.F. Liver biochemical tests and dengue fever. Am J Trop Med Hyg 1992, 47(3):265-270.
36. Souza L.J., Alves J.G., Nogueira R.M., Gicovate Neto C., Bastos D.A., Siqueira E.W., et al. Aminotransferase changes and acute hepatitis in patients with dengue fever: analysis of 1,585 cases. Braz J Infect Dis Off Publ Braz Soc Infect Dis 2004, 8(April (2)):156-163.
37. Kirkpatrick B.D., Durbin A.P., Pierce K.K., Carmolli M.P., Tibery C.M., Grier P.L., et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis 2015, 212(September (5)):702-710.
38. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Schmidt A.C., Whitehead S.S. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011, 29(42):7242-7250.
39. Gubler D.J., Reed D., Rosen L., Hitchcock J.R. Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga. Am J Trop Med Hyg 1978, 27(May (3)):581-589.
40. Blaney J.E., Hanson C.T., Hanley K.A., Murphy B.R., Whitehead S.S. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect Dis 2004, 4(October (1)):39.
41. Durbin A.P., Whitehead S.S., McArthur J., Perreault J.R., Blaney J.E., Thumar B., et al. rDEN4 Delta 30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005, 191(5):710-718.
42. Durbin A.P., McArthur J., Marron J.A., Blaney J.E., Thumar B., Wanionek K., et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2006, 2(July-August (4)):167-173.
43. Durbin A.P., McArthur J.H., Marron J.A., Blaney J.E., Thumar B., Wanionek K., et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2006, 2(6):255-260.
44. Statler J., Mammen M., Lyons A., Sun W. Sonographic findings of healthy volunteers infected with dengue virus. J Clin Ultrasound 2008.
45. Innis B.L., Eckels K.H., Kraiselburd E., Dubois D.R., Meadors G.F., Gubler D.J., et al. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J Infect Dis 1988, 158(4):876-880.
46. McKee K.T., Bancroft W.H., Eckels K.H., Redfield R.R., Summers P.L., Russell P.K. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg 1987, 36(2):435-442.
47. Fujita N., Oda K., Yasui Y., Hotta S. Research on dengue in tissue culture: IV. Serologic responses of human beings to combined inoculations of attenuated, tissue-cultured type 1 dengue virus and yellow fever vaccine. Kobe J Med Sci 1969, 15:163-180.
48. Eckels K.H., Scott R.M., Bancroft W.H., Brown J., Dubois D.R., Summers P.L., et al. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg 1984, 33(4):684-689.